Stockscreener 앱 받기
1.29
1.53%
-0.02
시간 외 거래:
1.30
0.01
+0.78%
전일 마감가:
$1.31
열려 있는:
$1.34
하루 거래량:
1.49M
Relative Volume:
1.11
시가총액:
$100.11M
수익:
$257.24M
순이익/손실:
$-237.89M
주가수익비율:
-0.4962
EPS:
-2.6
순현금흐름:
$-175.17M
1주 성능:
+11.21%
1개월 성능:
+41.73%
6개월 성능:
+25.24%
1년 성능:
-2.27%
1일 변동 폭
$1.2608
$1.37
1주일 범위
$1.13
$1.39
52주 변동 폭
$0.6603
$2.43
Coherus Oncology Inc Stock (CHRS) Company Profile
명칭
Coherus Oncology Inc
전화
(650) 649-3530
주소
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
CHRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.29 | 152.26M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-11-17 | 개시 | Robert W. Baird | Outperform |
| 2023-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-07-24 | 개시 | Citigroup | Buy |
| 2023-05-01 | 개시 | Truist | Buy |
| 2023-03-28 | 업그레이드 | UBS | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Neutral |
| 2022-03-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 개시 | BofA Securities | Neutral |
| 2020-04-17 | 개시 | SunTrust | Buy |
| 2019-08-13 | 개시 | Mizuho | Buy |
| 2019-08-02 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-02 | 재확인 | Maxim Group | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-07 | 개시 | H.C. Wainwright | Buy |
| 2018-08-28 | 개시 | H.C. Wainwright | Buy |
| 2018-03-09 | 재확인 | Maxim Group | Buy |
| 2017-08-08 | 재확인 | JP Morgan | Overweight |
| 2017-06-13 | 재확인 | Maxim Group | Buy |
| 2017-05-05 | 개시 | BMO Capital Markets | Outperform |
| 2016-10-19 | 개시 | Robert W. Baird | Outperform |
| 2016-09-07 | 개시 | Maxim Group | Buy |
| 2016-07-27 | 개시 | Citigroup | Buy |
| 2016-01-20 | 개시 | Credit Suisse | Outperform |
모두보기
Coherus Oncology Inc 주식(CHRS)의 최신 뉴스
Maxim Group upgrades Coherus Biosciences stock to Buy on oncology pivot - Investing.com
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Maxim Group Upgrades Coherus Oncology to Buy, Sets PT at $4 - AInvest
RSI Reset May Fuel Rebound in Coherus BioSciences Inc.July 2025 Sector Moves & Technical Pattern Recognition Alerts - beatles.ru
Coherus Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Leader Coherus Oncology Sets Major Conference Schedule: Baird, Wainwright, and UBS Events - Stock Titan
Backtesting results for Coherus BioSciences Inc. trading strategiesJuly 2025 Trends & Real-Time Market Sentiment Alerts - Newser
Can machine learning forecast Coherus BioSciences Inc. recoveryTrade Analysis Summary & Safe Capital Allocation Plans - Newser
Relative strength of Coherus BioSciences Inc. in sector analysisMarket Movement Recap & Daily Profit Focused Stock Screening - Newser
Coherus Oncology: On The Shaping Up (NASDAQ:CHRS) - Seeking Alpha
Penny Stocks to Watch: Lantronix and Coherus Oncology Among Top Picks - AInvest
Lobbying Update: $125,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2025 Earnings Call Transcript - Insider Monkey
Coherus Oncology’s Earnings Call Highlights Growth and Challenges - TipRanks
Analysts' Revenue Estimates For Coherus Oncology, Inc. (NASDAQ:CHRS) Are Surging Higher - 富途牛牛
Coherus Oncology's (CHRS) Strategic Reinvention: A High-Conviction Biotech Play for the Long Term - AInvest
Industry Analysts Just Upgraded Their Coherus Oncology, Inc. (NASDAQ:CHRS) Revenue Forecasts By 21% - simplywall.st
Need To Know: Analysts Are Much More Bullish On Coherus Oncology, Inc. (NASDAQ:CHRS) Revenues - Yahoo Finance
Coherus Oncology 2025 Q2 Earnings Strong Turnaround with 2404.5% Net Income Surge - AInvest
Coherus Oncology shares rise 4.07% premarket after Q2 revenue up 36%. - AInvest
Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips - Investing.com
Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips By Investing.com - Investing.com South Africa
Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Coherus (CHRS) Q2 Revenue Jumps 10% - AOL.com
Coherus Oncology Reports Strong Q2 2025 Growth - TipRanks
Coherus Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - 富途牛牛
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Coherus Oncology: Q2 Earnings Snapshot - San Antonio Express-News
Coherus Oncology Q2 2025: LOQTORZI revenue up 36% to $10.0mln. - AInvest
Coherus Oncology Reports Second Quarter 2025 Financial Results a - GuruFocus
Coherus Oncology Reports 36% Increase in LOQTORZI Net Revenue for Q2 2025 and Updates on Pipeline Progress - Quiver Quantitative
Transcript : Coherus Oncology, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Insights Ahead: Coherus BioSciences's Quarterly Earnings - 富途牛牛
Coherus Oncology, Inc. (NASDAQ:CHRS) is largely controlled by institutional shareholders who own 54% of the company - Yahoo Finance
Coherus Oncology Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
What is Coherus BioSciences Inc. company’s growth strategyLightning-fast capital gains - Jammu Links News
Earnings Preview: CHRS to Report Financial Results Post-market on August 07 - 富途牛牛
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 | CHRS Stock News - GuruFocus
Coherus Oncology to Release Second Quarter 2025 Financial Results on August 7, 2025 - Quiver Quantitative
Coherus Earnings: Q2 2025 Results and Management Call Set for August 7 After Market Close - Stock Titan
Why Coherus BioSciences Inc. stock attracts strong analyst attentionHigh Reward Risk Balanced Trading - metal.it
Coherus Oncology, Inc.'s (NASDAQ:CHRS) Price Is Right But Growth Is Lacking After Shares Rocket 35% - simplywall.st
Positive week for Coherus Oncology, Inc. (NASDAQ:CHRS) institutional investors who lost 47% over the past year - simplywall.st
Alvotech: A Fast Expanding Biosimilar Concern (NASDAQ:ALVO) - Seeking Alpha
Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Are Reducing Their Forecasts For This Year - 富途牛牛
Coherus Biosciences Receives Nasdaq Deficiency Notice - TipRanks
Coherus Oncology Inc (CHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):